School of Biomedical Sciences, University of Nottingham Medical School, Queen's Medical Center, Nottingham NG7 2UH, UK.
Neuroscience. 2010 Mar 10;166(1):15-22. doi: 10.1016/j.neuroscience.2009.11.073. Epub 2009 Dec 17.
Valproic acid (VPA) is widely used clinically, as an anticonvulsant and mood stabilizer but is, however, also known to block cell proliferation through its ability to inhibit histone deacetylase enzymes. There have been a number of reports of cognitive impairments in patients taking VPA. In this investigation we examined the relationship between cognition and changes in cell proliferation within the hippocampus, a brain region where continued formation of new neurons is associated with learning and memory. Treatment of rats by i.p. injection of VPA, reduced cell proliferation in the sub granular zone of the dentate gyrus within the hippocampus. This was linked to a significant impairment in their ability to perform a hippocampus-dependent spatial memory test (novel object location). In addition, drug treatment caused a significant reduction in brain-derived neurotrophic factor (BDNF) and Notch 1 but not doublecortin levels within the hippocampus. These results support the idea that VPA may cause cognitive impairment and provide a possible mechanism for this by reducing neurogenesis within the hippocampus.
丙戊酸(VPA)在临床上被广泛应用,作为一种抗惊厥药和情绪稳定剂,但它也通过抑制组蛋白去乙酰化酶来阻止细胞增殖。有许多报道称服用 VPA 的患者存在认知障碍。在这项研究中,我们研究了认知与海马内细胞增殖变化之间的关系,海马是一个与学习和记忆相关的持续产生新神经元的脑区。通过腹腔注射 VPA 治疗大鼠,导致海马齿状回颗粒下层的细胞增殖减少。这与它们在执行海马依赖性空间记忆测试(新物体位置)的能力显著受损有关。此外,药物治疗导致海马内脑源性神经营养因子(BDNF)和 Notch1 水平显著降低,但双皮质素水平没有降低。这些结果支持 VPA 可能导致认知障碍的观点,并通过减少海马内的神经发生提供了一种可能的机制。